Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland
Authors:
Open Access
- 9 June 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 7814-7824
Abstract
Aim: This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland. Materials and Methods: Adults living with T2D ( n = 7249) who initiated oral semaglutide between April 1, 2021, and December 31, 2023, were identified from national registers and followed until June 30, 2024. Primary endpoints were changes in HbA1c and body weight from baseline to 182.5 and 365 days. Secondary endpoints included changes in LDL‐cholesterol, HDL‐cholesterol, total cholesterol, triglycerides, HDL/triglycerides ratio, and ALT. Results: Of those initiating oral semaglutide, 65.8% remained on treatment at 180 days and 55.2% at 365 days. Among patients included in longitudinal trajectory modelling, mean HbA1c ( n = 2784) decreased from 7.9% to 6.8% at 182.5 days (95% CI: −1.20 to −1.04; p < 0.001) and to 6.9% at 365 days (95% CI: −1.18 to −0.95; p < 0.001). Mean body weight ( n = 832) declined from 106 to 100 kg at 182.5 days (95% CI: −7 to −5; p < 0.001) and to 98 kg at 365 days (95% CI: −10 to −6; p < 0.001). LDL‐cholesterol ( n = 1402), and triglycerides ( n = 975) were significantly reduced at 182.5 days with little further change at 365 days. Mean ALT ( n = 1762) declined from 50 to 42 U/L at 182.5 days (95% CI: −10 to −6, p < 0.001) and to 37 U/L at 365 days (; 95% CI: −16 to −10; p < 0.001). While weight at baseline was lower at patients aged at least 75 years, the changes in HbA1c and weight were similar compared to patients under 75 years of age. Conclusion: Oral semaglutide significantly improves glycaemic and lipid control, body weight, and liver enzymes in adults living with T2D treated in clinical practice.Keywords
Funding Information
- Novo Nordisk Pharma
This publication has 16 references indexed in Scilit:
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesNew England Journal of Medicine, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical PracticeClinical Therapeutics, 2024
- Adherence to glucagon‐like peptide ‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry studyDiabetes, Obesity and Metabolism, 2024
- Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024Journal of Clinical Lipidology, 2024
- Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study ( PIONEER REAL Canada)Diabetes, Obesity and Metabolism, 2024
- Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutideDiabetes, Obesity and Metabolism, 2024
- Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( ENDO 2 S‐RWD )Diabetes, Obesity and Metabolism, 2023
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2019
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With SulfonylureaJAMA, 2019